Michito Ubukata

418 total citations
9 papers, 316 citations indexed

About

Michito Ubukata is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Michito Ubukata has authored 9 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Surgery. Recurrent topics in Michito Ubukata's work include Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (7 papers) and Pancreatic function and diabetes (5 papers). Michito Ubukata is often cited by papers focused on Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (7 papers) and Pancreatic function and diabetes (5 papers). Michito Ubukata collaborates with scholars based in Japan. Michito Ubukata's co-authors include Yoshishige Samukawa, Soichi Sakai, Takashi Sasaki, Atsushi Fukatsu, Yutaka Seino, Nobuya Inagaki, Masakazu Haneda, Kohei Kaku, Takeshi Osonoi and Shigeto Kanada and has published in prestigious journals such as Diabetes Obesity and Metabolism, Diabetes Research and Clinical Practice and Biotechnology Letters.

In The Last Decade

Michito Ubukata

9 papers receiving 307 citations

Peers

Countries citing papers authored by Michito Ubukata

Since Specialization

Citations

This map shows the geographic impact of Michito Ubukata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michito Ubukata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michito Ubukata more than expected).

Fields of papers citing papers by Michito Ubukata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michito Ubukata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michito Ubukata. The network helps show where Michito Ubukata may publish in the future.

Co-authorship network of co-authors of Michito Ubukata

This figure shows the co-authorship network connecting the top 25 collaborators of Michito Ubukata. A scholar is included among the top collaborators of Michito Ubukata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michito Ubukata. Michito Ubukata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males 2015 ·Advances in Therapy ·Takashi Sasaki, Yutaka Seino, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa	10
2	Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial 2015 ·Advances in Therapy ·Takashi Sasaki, Yutaka Seino, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa	18
3	Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in J apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study 2015 ·Diabetes Obesity and Metabolism ·Rimei Nishimura, Takeshi Osonoi, Shigeto Kanada, Hideaki Jinnouchi, Kazuo Sugio, (unknown), Michito Ubukata, Soichi Sakai, Yoshishige Samukawa	43
4	Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise 2015 ·Endocrine Journal ·Yutaka Seino, Kohei Kaku, Nobuya Inagaki, Masakazu Haneda, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa	23
5	Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus 2014 ·Journal of Diabetes Investigation ·Yutaka Seino, Nobuya Inagaki, Masakazu Haneda, Kohei Kaku, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa	48
6	Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study 2014 ·Current Medical Research and Opinion ·Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa	113
7	PO433 EFFICACY AND SAFETY OF LUSEOGLIFLOZIN IN YOUNGER AND ELDERLY JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS: ANALYSIS OF POOLED DATA FROM LONG-TERM PHASE 3 TRIALS 2014 ·Diabetes Research and Clinical Practice ·Michito Ubukata, (unknown), Yoshishige Samukawa, (unknown), Masakazu Haneda, Nobuya Inagaki, Kohei Kaku, Y. Seino	1
8	Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study 2014 ·Current Medical Research and Opinion ·Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa	51
9	Assessment of small ligand-protein interactions by electrophoretic mobility shift assay using DNA-modified ligand as a sensing probe 2007 ·Biotechnology Letters ·Hisakage Funabashi, Michito Ubukata, Takashi Ebihara, Masuo Aizawa, Masayasu Mie, Eiry Kobatake	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact